Lilly Zepbound (10 mg and 15 mg) linked to more weight loss than Wegovy HD, Reuters says
Reuters reports an indirect treatment comparison showing Zepbound 10 mg and 15 mg associated with greater weight loss than Wegovy HD at 72 weeks, with Zepbound 15 mg users having higher odds of 20% reduction.
Sept 29 (Reuters) — Eli Lilly and Company said a new indirect treatment comparison found that Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg). The company said Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesity. It added that Zepbound 10 mg and 15 mg had comparable adverse event discontinuation rates to Wegovy HD. Eli Lilly said Zepbound produced 20.2% weight reduction versus 13.7% for Wegovy at 72 weeks, and that Zepbound 15 mg users had over three times the odds of 20% weight reduction versus Wegovy HD.